Year: 2024

Pharmacokinetic and safety data from healthy volunteers anticipated in the second half of 2025 On track to initiate a proof-of-concept study in psoriasis in the second half of 2025, with initial efficacy data expected in the second half of 2026 Preclinical data with ORKA-001 demonstrate the potential for once- or twice-yearly dosing, a significant improvement over standard of care MENLO PARK, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) — Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced that it has initiated dosing of healthy volunteers in its first clinical trial of ORKA-001, the Company’s novel, subcutaneously administered, half-life extended monoclonal antibody...

NEW YORK, Dec. 19, 2024 (GLOBE NEWSWIRE) — OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Metaplanet Inc. (TSE: 3350; OTCQX: MTPLF), Japan’s first publicly traded company on a Bitcoin standard, has qualified to trade on the OTCQX® Best Market. Metaplanet Inc. begins trading today on OTCQX under the symbol “MTPLF.” This marks an important milestone as the company expands access to global investors and reinforces its mission to drive Bitcoin adoption. U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com. Upgrading to the OTCQX Market is an important step for companies seeking to provide transparent trading for their U.S. investors. For companies listed on a qualified international...

Fast track designation follows positive Phase 1 data presented at the 12th International Workshop on Waldenstrom’s Macroglobulinemia SAN FRANCISCO, Dec. 19, 2024 (GLOBE NEWSWIRE) — Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for NX-5948, a highly selective degrader of Bruton’s tyrosine kinase (BTK), for the treatment of adult patients with relapsed or refractory Waldenstrom’s macroglobulinemia (WM) after at least two lines of therapy, including a BTK inhibitor. “Fast Track designation for NX-5948 is an important recognition of the unmet patient need in Waldenstrom’s macroglobulinemia,...

NEW YORK, Dec. 19, 2024 (GLOBE NEWSWIRE) — Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer’s disease, today announced that Dr. Kyle Rasbach has been appointed Chief Financial Officer, effective immediately. Dr. Rasbach brings a wealth of life sciences experience to the company and joins ahead of multiple anticipated catalysts across its gene therapy programs. “Kyle has an exceptional track record as an operator and life sciences portfolio manager, and we are excited to welcome him to Lexeo at a time when we are advancing our pipeline and transitioning towards pivotal studies,” said R. Nolan Townsend, Chief Executive Officer of Lexeo Therapeutics. “His experience in strategic planning,...

Preclinical Studies Confirmed BP1001-A Mechanism of Action and Therapeutic Potential in Obesity and Type 2 Diabetes HOUSTON, Dec. 19, 2024 (GLOBE NEWSWIRE) — Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today reported that results from preclinical studies of BP1001-A for obesity demonstrated enhanced insulin sensitivity, confirming BP1001-A as a potential treatment for obesity and related metabolic diseases in Type 2 diabetes patients. BP1001-A downregulates growth factor receptor-bound protein 2 (Grb2) expression to increase insulin sensitivity and helps lower blood glucose level in Type 2 diabetes patients. Scientific evidence suggests that by downregulating Grb2 expression,...

– Completed US$7.7 million financing and reverse takeover to take Company public – Chinese partner achieved regulatory approval, setting stage for royalty stream and triggering US$5.9 million payment, enabling Company to fully repay debt to that partner – U.S. FDA submission of Novasight 3.0 system on track for calendar 2025 TORONTO, Dec. 19, 2024 (GLOBE NEWSWIRE) — Conavi Medical Corp. (TSXV: CNVI) (“Conavi Medical” or the “Company”), a commercial stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures, today reported financial results for the fiscal year ended September 30, 2024. These results are presented in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board. “With...

VANCOUVER, British Columbia, Dec. 19, 2024 (GLOBE NEWSWIRE) — Nevada Lithium Resources Inc. (“Nevada Lithium” or the “Company“) (CSE: NVLH; OTCQB: NVLHF; FSE: 87K) is pleased to announce that it has received conditional approval from the TSX Venture Exchange (the “TSXV”) for the listing of its common shares (the “Shares”) on the TSXV, subject to completion of customary requirements of the TSXV, including receipt of all required documentation. Once final approval is received, the Shares will commence trading on the TSXV and will be delisted from the Canadian Securities Exchange (the “CSE”). Upon listing on the TSXV, it is expected that the Shares will continue to trade under the ticker symbol “NVLH”. The Company is pursuing a listing on the TSXV to enhance its investor profile as a part of its capital markets...

Business update to include masked Phase 3 patient demographics and baseline characteristics Presentation on Wednesday, January 15, 2025, 5:15 PM PT in San Francisco, California MELBOURNE, Australia and PRINCETON, N.J., Dec. 19, 2024 (GLOBE NEWSWIRE) — Opthea Limited (ASX/NASDAQ:OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that Frederic Guerard, PharmD, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, California on Wednesday, January 15, 2025 at 5:15 PM PT. Dr. Guerard will provide an update on the business, including masked patient demographics and baseline characteristics from the...

SAN DIEGO, Dec. 19, 2024 (GLOBE NEWSWIRE) — Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, will present a corporate overview at the 43rd Annual J.P. Morgan Healthcare conference on Thursday, January 16, 2025, at 10:30 AM – 11:10 AM. A live and archived webcast will be accessible on Skye’s website. About Skye Bioscience Skye is focused on unlocking new therapeutic pathways for metabolic health through the development of next-generation molecules that modulate G-protein coupled receptors. Skye’s strategy leverages biologic targets with substantial human proof of mechanism for the development of first-in-class therapeutics with clinical and commercial differentiation. Skye is conducting...

WELLESLEY HILLS, Mass., Dec. 19, 2024 (GLOBE NEWSWIRE) — December 19, 2024 – Climb Bio, Inc. (Nasdaq: CLYM) today announced that the company will be added to the NASDAQ Biotech Index (Nasdaq: NBI) as part of the annual reconstitution of the 2024 Nasdaq indexes. Climb Bio’s inclusion in the Nasdaq Biotechnology Index will be effective prior to market open on Monday, December 23, 2024. The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on The Nasdaq Stock Market® (Nasdaq®) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB). The NASDAQ Biotechnology Index is calculated under a modified capitalization-weighted methodology. Companies in the NASDAQ Biotechnology Index must meet eligibility requirements, including minimum...